03 April 2019 DEVELOPMENT OF A COST-EFFECTIVE PERSONALIZED CANCER NEOANTIGEN VACCINES INDUCING A UNIQUE CD8-DOMINATED T CELL RESPONSE | Basel, October 2018 Download Go back
